Legal & General Group Plc Has $697,000 Stake in Autolus Therapeutics plc (NASDAQ:AUTL)

Legal & General Group Plc increased its stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 392.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 297,736 shares of the company's stock after buying an additional 237,224 shares during the quarter. Legal & General Group Plc owned about 0.11% of Autolus Therapeutics worth $697,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in AUTL. Wellington Management Group LLP boosted its position in Autolus Therapeutics by 4.6% in the fourth quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company's stock valued at $59,562,000 after buying an additional 1,125,454 shares in the last quarter. Candriam S.C.A. acquired a new stake in shares of Autolus Therapeutics during the 4th quarter valued at $7,500,000. JPMorgan Chase & Co. boosted its holdings in shares of Autolus Therapeutics by 145.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company's stock valued at $4,663,000 after acquiring an additional 761,008 shares in the last quarter. BIT Capital GmbH grew its position in Autolus Therapeutics by 147.0% during the 4th quarter. BIT Capital GmbH now owns 636,979 shares of the company's stock worth $1,497,000 after acquiring an additional 379,050 shares during the last quarter. Finally, State Street Corp increased its holdings in Autolus Therapeutics by 1.7% in the 3rd quarter. State Street Corp now owns 606,544 shares of the company's stock worth $2,202,000 after purchasing an additional 10,401 shares in the last quarter. Institutional investors own 72.83% of the company's stock.

Analyst Ratings Changes

Several analysts have recently weighed in on AUTL shares. Needham & Company LLC restated a "buy" rating and set a $10.00 price target on shares of Autolus Therapeutics in a report on Thursday, April 10th. Wells Fargo & Company reduced their target price on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a report on Friday, March 21st. Finally, Truist Financial reduced their price target on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $9.32.

Autolus Therapeutics Trading Down 4.3 %

AUTL stock traded down $0.06 during mid-day trading on Thursday, reaching $1.35. The company's stock had a trading volume of 1,355,422 shares, compared to its average volume of 1,447,912. Autolus Therapeutics plc has a 12 month low of $1.11 and a 12 month high of $5.00. The business's 50 day moving average price is $1.60 and its 200 day moving average price is $2.41. The company has a market cap of $359.23 million, a price-to-earnings ratio of -1.12 and a beta of 2.06.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.12. The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $2.98 million. As a group, equities analysts expect that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.